Patent ID: 7598288

Claim:
A method for treating glaucomatous optic neuropathy comprising administering to a patient in need thereof a therapeutically effective amount of a composition comprising at least one glycogen synthase kinase-3 (GSK-3) inhibitor in a pharmaceutically acceptable carrier, wherein said GSK-3 inhibitor is a compound of the formula: wherein R 1 and R 2 independently═ R 3 ═H, C 1-6 alkyl, (un)substituted phenyl, C 1-6 alkyl-NR 6 R 7 , C 1-7 cycloalkyl, C 1-6 alkyl-OR 6 , C 1-6 alkylC(O) 2R5 , or C 1-6 alkylC(O)NR 6 R 7 ; R 4 ═H, or one or more substituents C 1-6 alkyl, (un)substituted phenyl, —OR 6 , —SR 6 , halogen, (un)substituted phenoxy, —CN, —NO 2 , C 1-6 alkyl-NR 6 R 7 , —NR 6 R 7 , C 1-7 cycloalkyl, (un)substituted heterocyclyl, —C(O) 2 R 5 , C 1-6 alkylC(O) 2 R 5 , or C 1-6 alkylC(O)NR 6 R 7 ; and R 5 , R 6 , R 7 ═H, or C 1-6 alkyl, (un)substituted phenyl.